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Background
Dysregulation in membrane protein activity is often a pri-
mary step in human diseases. One of the major difficulties
in the study of membrane proteins is to recover a large
enough amount of recombinant proteins from the classi-
cal overexpression techniques. We have recently demon-
strated the effectiveness of a cell-free expression system in
production of membrane proteins. The membrane pro-
teins are produced in a soluble form without the require-
ment of a denaturation step. Most of the membrane
proteins tested in this expression system are with native-
like conformation whatever the presence or not of lipid
vesicles. Here, we examplify our protein expression sys-
tem on membrane proteins from different origins: the
mammalian gp91-phox protein, the large subunit of the
flavocytochrome b558, the mitochondrial voltage-
dependent anion channel, VDAC, and the chloroplastic
outer envelope protein from pea, OEP24.
Results
Gp91phox is an integrated transmembrane protein con-
taining the catalytic activity of the reducing NADPH oxi-
dase complex. Full length or truncated gp91-phox
proteins were expressed in soluble forms in E. coli lysate in
presence of non ionic detergents and in an oxidizing envi-
ronment. Activities of the resulting proteins were tested in
an electron transfer assay. Some of these gp91-truncated
forms contained an enzymatic activity alike to the cellular
counterpart. For these truncated proteins, scale-up experi-
ments have been performed in order to use the purified
proteins in crystallographic studies and structural analy-
sis. VDAC and OEP24 membrane proteins were over-
expressed at 230 μg/ml and 360 μg/ml respectively in our
optimized cell-free protein synthesis system. Proteins are
integrated in lipid vesicles in presence of detergents result-
ing in proteoliposomes. In presence of liposomes, OEP24
protein was recovered as dimers suggesting that OEP24
protein is functional. The OEP24 in proteoliposomes
forms a cation-selective channel as measured by changes
in suspension turbidity in presence of KCl or sucrose.
Activity of recombinant VDAC proteoliposomes was
directly tested on mammalian cells by adding the VDAC
proteoliposomes on cells and by measuring the cyto-
chrome c release and activation of apoptosis. Immunoflu-
orescence studies using anti-VDAC and anti-His
antibodies indicate that recombinant VDAC is targeted to
the mitochondria.
Conclusion
In conclusion, our recombinant technology to produce
membrane proteins in their native conformations repre-
sents a new strategy for providing insights into functional
and structural informations on membrane proteins.
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